Gene therapy injection aims to save sight in rare eye disease
Disease control
Recruiting now
This early-phase trial tests a new gene therapy called VG801 for Stargardt disease, a genetic condition that causes vision loss. Fifteen people aged 6 and older will receive a single injection under the retina. The main goal is to check safety, but researchers will also measure a…
Phase: PHASE1, PHASE2 • Sponsor: VeonGen Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC